PMID- 23633287
OWN - NLM
STAT- MEDLINE
DCOM- 20140103
LR  - 20220310
IS  - 1097-4547 (Electronic)
IS  - 0360-4012 (Print)
IS  - 0360-4012 (Linking)
VI  - 91
IP  - 7
DP  - 2013 Jul
TI  - Estrogen receptor-beta ligand treatment after disease onset is neuroprotective in 
      the multiple sclerosis model.
PG  - 901-8
LID - 10.1002/jnr.23219 [doi]
AB  - Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation 
      and neurodegeneration. Current MS treatments were designed to reduce inflammation 
      in MS rather than directly to prevent neurodegeneration. Estrogen has 
      well-documented neuroprotective effects in a variety of disorders of the CNS, 
      including experimental autoimmune encephalomyelitis (EAE), the most widely used 
      mouse model of MS. Treatment with an estrogen receptor-beta (ERbeta) ligand is known to 
      ameliorate clinical disease effectively and provide neuroprotection in EAE. 
      However, the protective effects of this ERbeta ligand have been demonstrated only 
      when administered prior to disease (prophylactically). Here we tested whether ERbeta 
      ligand treatment could provide clinical protection when treatment was initiated 
      after onset of disease (therapeutically). We found that therapeutic treatment 
      effectively ameliorated clinical disease in EAE. Specifically, ERbeta ligand-treated 
      animals exhibited preserved axons and myelin compared with vehicle-treated 
      animals. We observed no difference in the number of T lymphocytes, macrophages, 
      or microglia in the CNS of vehicle- vs. ERbeta ligand-treated animals. Our findings 
      show that therapeutically administered ERbeta ligand successfully treats clinical 
      EAE, bearing translational relevance to MS as a candidate neuroprotective agent.
CI  - Copyright (c) 2013 Wiley Periodicals, Inc.
FAU - Wisdom, Amy J
AU  - Wisdom AJ
AD  - UCLA Multiple Sclerosis Program, Department of Neurology, University of 
      California, Los Angeles, California 90095, USA.
FAU - Cao, Yuan
AU  - Cao Y
FAU - Itoh, Noriko
AU  - Itoh N
FAU - Spence, Rory D
AU  - Spence RD
FAU - Voskuhl, Rhonda R
AU  - Voskuhl RR
LA  - eng
GR  - T32 HD007228/HD/NICHD NIH HHS/United States
GR  - P30 HD004612/HD/NICHD NIH HHS/United States
GR  - K24 NS062117/NS/NINDS NIH HHS/United States
GR  - R01 NS045443/NS/NINDS NIH HHS/United States
GR  - HHMI/Howard Hughes Medical Institute/United States
GR  - 5T32HD07228/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130430
PL  - United States
TA  - J Neurosci Res
JT  - Journal of neuroscience research
JID - 7600111
RN  - 0 (2,3-bis(4-hydroxyphenyl)-propionitrile)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Nitriles)
RN  - 0 (Peptide Fragments)
RN  - 0 (Propionates)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (myelin oligodendrocyte glycoprotein (35-55))
RN  - 9007-81-2 (Freund's Adjuvant)
SB  - IM
MH  - Animals
MH  - Axons/drug effects
MH  - Demyelinating Diseases/etiology/prevention & control
MH  - Disease Models, Animal
MH  - Encephalomyelitis, Autoimmune, Experimental/chemically 
      induced/complications/*drug therapy
MH  - Female
MH  - Freund's Adjuvant/toxicity
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Myelin-Oligodendrocyte Glycoprotein/immunology
MH  - Neuroprotective Agents/*therapeutic use
MH  - Nitriles/*therapeutic use
MH  - Peptide Fragments/immunology
MH  - Propionates/*therapeutic use
MH  - Receptors, Estrogen/*agonists
MH  - Severity of Illness Index
PMC - PMC4376676
MID - NIHMS570484
EDAT- 2013/05/02 06:00
MHDA- 2014/01/05 06:00
PMCR- 2015/03/27
CRDT- 2013/05/02 06:00
PHST- 2012/10/18 00:00 [received]
PHST- 2013/01/19 00:00 [revised]
PHST- 2013/02/14 00:00 [accepted]
PHST- 2013/05/02 06:00 [entrez]
PHST- 2013/05/02 06:00 [pubmed]
PHST- 2014/01/05 06:00 [medline]
PHST- 2015/03/27 00:00 [pmc-release]
AID - 10.1002/jnr.23219 [doi]
PST - ppublish
SO  - J Neurosci Res. 2013 Jul;91(7):901-8. doi: 10.1002/jnr.23219. Epub 2013 Apr 30.